In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacokinetic trial of Medidur begins:

This article was originally published in Clinica

Executive Summary

Alimera Sciences and pSivida have kicked off the first human pharmacokinetic trial of Medidur, the companies' drug-eluting implant for the treatment of diabetic macular oedema. Medidur is injected intra-vitreally and delivers a very low dose of fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years. The new three-year study will also provide information on the location of Medidur FA in the eye after insertion and drug levels in the anterior chamber. Currently in a global phase III trial in around 900 patients, the device is the subject of a co-development agreement between Alimera, of Alpharetta, Georgia, and Perth, Australia-based pSivida.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts